Office for Research on Aging, St Louis College of Pharmacy, St Louis, Missouri, USA.
J Geriatr Psychiatry Neurol. 2010 Mar;23(1):63-9. doi: 10.1177/0891988709342723. Epub 2009 Aug 7.
Associations between medication use and the development of Alzheimer disease have been investigated since the late 1900s. Thyroid hormone supplementation is rarely a studied medication class in this area of research. We examined data from participants enrolled in longitudinal studies at the Washington University Alzheimer's Disease Research Center for associations between thyroid disease, thyroid hormone supplementation therapy, and subsequent development of dementia of the Alzheimer type (DAT). Data collected between April 1992 and June 2008 from 499 participants, 184 men and 315 women, were analyzed. Mean age was 76.9 years (SD = 9.2). At baseline, 61 participants reported thyroid medication use and 87 were identified as having a history of thyroid dysfunction. These participants progressed to a DAT diagnosis more rapidly than individuals not taking thyroid medication (hazard ratios [HR]: 1.67, 95% CI: 0.99-2.78, P = .054). Although an interesting trend was seen, baseline thyroid disease was not significantly (P = .093) associated with time to DAT diagnosis. Our findings suggest that utilization of thyroid medication may be associated with the development of DAT.
自 20 世纪末以来，人们一直在研究药物使用与阿尔茨海默病发展之间的关系。在这一研究领域中，甲状腺激素补充剂很少被作为一种研究药物类别进行研究。我们检查了参加华盛顿大学阿尔茨海默病研究中心纵向研究的参与者的数据，以研究甲状腺疾病、甲状腺激素补充治疗与随后发生的阿尔茨海默病型痴呆（DAT）之间的关系。对 1992 年 4 月至 2008 年 6 月期间收集的 499 名参与者（184 名男性和 315 名女性）的数据进行了分析。平均年龄为 76.9 岁（标准差=9.2）。在基线时，61 名参与者报告使用甲状腺药物，87 名参与者被确定有甲状腺功能障碍病史。与未服用甲状腺药物的个体相比，这些参与者进展为 DAT 诊断的速度更快（风险比 [HR]：1.67，95%置信区间：0.99-2.78，P=0.054）。尽管出现了有趣的趋势，但基线甲状腺疾病与 DAT 诊断时间无显著相关性（P=0.093）。我们的研究结果表明，甲状腺药物的使用可能与 DAT 的发展有关。
